CurrentCapital BluecrossPolicy MP 2.323

MEDICAL POLICY - GENERAL APPROACH TO EVALUATING THE UTILITY OF GENETIC PANELS

Framework and criteria for assessing medical necessity of genetic panels (NGS or chromosomal microarray) across categories (hereditary/genetic conditions, cancer, reproductive) when no more specific policy exists. Includes technical, clinical utility, counseling, and coding guidance; not a description of benefit coverage for specific plans.

Policy Summary

PayerCapital Bluecross

PolicyMEDICAL POLICY - GENERAL APPROACH TO EVALUATING THE UTILITY OF GENETIC PANELS

Policy CodePolicy MP 2.323

Change TypeAdministrative / clarified

Effective DateFeb 1, 2025

Next Review Date

Key ActionVerify that no separate Capital Blue Cross medical policy exists for the specific genetic test; if one exists, apply that policy's criteria instead of this general policy.

SourceLink

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

POLICY UPDATE CHANGES

Policy history notes administrative updates and consensus reviews with no changes to the policy statement on 05/11/2020, 05/20/2022, 09/29/2023, and 10/24/2024.

3Major panel categories

81410-81471, 815XX, 81479, 0001U-0153U, 0362UKey CPT/PLA/MAAA codes referenced

CLIALaboratory requirement

Coverage Summary

This policy provides a framework for assessing the medical necessity of genetic panels (including next-generation sequencing and chromosomal microarray) when no separate, test-specific medical policy exists. It is intended to guide whether a panel is a reasonable alternative to individual tests when at least one variant in the panel has established clinical utility and clinical indications for testing are present.

Scope includes major panel categories — hereditary/genetic conditions, cancer, and reproductive panels — and covers technical, clinical utility, counseling, and coding considerations for evaluating panels in the absence of a superseding policy.

Quick facts and thresholds

Major panel categories3

Key CPT/PLA/MAAA codes referenced81410-81471, 815XX, 81479, 0001U-0153U, 0362U

Laboratory requirementCLIA

Diagnostic yield guidance>= 10% in symptomatic patients

CMA yield5% to 20%

Cancer susceptibility yield2% to 10%

Medically Necessary Criteria

General applicability

This policy applies only if there is no separate medical policy that outlines specific criteria for testing; if a separate policy exists, that policy supersedes this one.

Test is a genetic panel using next-generation sequencing (NGS), massive parallel sequencing, or chromosomal microarray analysis (does not include gene expression profiling).
There is no separate policy for the specific test; if a separate policy exists (e.g., genetic cancer susceptibility panels MP 2.325, expanded molecular panel testing MP 2.259, preimplantation testing MP 7.009), that policy's criteria supersede this policy.

Medically necessary when ALL criteria are met for each panel category

Genetic panels may be considered medically necessary when all criteria listed for the applicable category are met.

Applicable panel categories (ONE of)

Coding Guidance

Next-generation sequencing panel CPT codes (specific genomic sequencing procedures)CPT

81410	CPT genomic sequencing procedure
81411	CPT genomic sequencing procedure
81412	CPT genomic sequencing procedure
81413	CPT genomic sequencing procedure
81414	CPT genomic sequencing procedure
81415	CPT genomic sequencing procedure
81416	CPT genomic sequencing procedure
81417	CPT genomic sequencing procedure
81418	CPT genomic sequencing procedure
81419	CPT genomic sequencing procedure

1–10 of 35

1/4

Tier 1 / Tier 2 specific analyte CPT guidance and unlisted codesCPT

81105	Tier analyte (example) - report specific analyte CPT if panel analytes listed
81107	Tier analyte (example)
81400	Tier 2 genomic sequencing analyte codes (example range 81400-81408 referenced)
81479	Unlisted molecular pathology procedure (used once for analytes not listed)

Multianalyte assays with algorithmic analysis (MAAA)CPT

815XX	Specific codes in 815XX section for MAAA when algorithmic numeric score/probability produced
81599	Unlisted MAAA code if no specific code exists

AMA Proprietary Laboratory Analyses (PLA) codesCPT

0001U-0153U	PLA codes subject to above criteria as appropriate
0362U	PLA code added per policy history

Provider Actions & Billing Guidance

Documentation Required

Confirm absence of a more specific policy

Verify that no separate Capital Blue Cross medical policy exists for the specific genetic test. If a more specific policy exists (for example, genetic cancer susceptibility panels, expanded molecular panel testing, or preimplantation testing), that policy's criteria supersede this general policy. Operational note: check cross-references and product-specific policies before applying this general panel policy.

Documentation Required

Laboratory CLIA requirement

Ensure testing is performed in a CLIA-licensed laboratory for high-complexity testing and that analytic validity and methods are documented. The laboratory must deliver reproducible, quality-filtered variant calls and describe analytic validity so that sensitivity/specificity are clinically acceptable.

Documentation Required

Define clinical utility and decision plan

Document the intended use of testing and a pre-defined decision plan: specify how results will change diagnosis or treatment consistent with current standard of care, outline potential incidental findings and downstream impacts (further testing, management changes, reproductive implications), and ensure expected clinical utility is established for at least one variant in the panel.

Background and Definitions

Next-generation sequencing and chromosomal microarray panels can approach the analytic validity of direct Sanger sequencing and are defined as tests that evaluate multiple genes simultaneously, but panel composition varies across laboratories and over time. Panels can generate abundant ancillary information, including variants of uncertain significance and incidental findings that may lead to incorrect risk assessment or unnecessary invasive follow-up. Because of these potential harms and complexity, genetic counseling by individuals with expertise in genetic medicine is recommended for at-risk patients both before and after testing. This policy specifically focuses on panels performed by NGS, massive parallel sequencing, or chromosomal microarray and excludes gene expression profiling.

Published comparisons report that analytic concordance between NGS and Sanger sequencing has been > 99% in several studies for cancer susceptibility testing and inherited disorders, although published data are limited. The summary of evidence notes that analytic validity of panels generally approaches that of direct sequencing, while clinical validity and utility remain condition-specific.

Term	Definition
Genetic panel
A test that simultaneously evaluates multiple genes (includes next-generation sequencing, massive parallel sequencing, chromosomal microarray); excludes gene expression profiling.
Variant classification (ACMG-AMP)
Standard terminology per ACMG-AMP: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, benign.

Revision History

01/01/2020coding update

Administrative update: removed deleted PLA code 0104U and added new PLA codes 0152U and 0153U (policy statements unchanged).

05/11/2020consensus review

Consensus review — policy statements unchanged; tables and references updated.

05/20/2022consensus review

Consensus review — references updated and FEP section updated; no changes to policy statement.

Policy Summary

PayerCapital Bluecross

PolicyMEDICAL POLICY - GENERAL APPROACH TO EVALUATING THE UTILITY OF GENETIC PANELS

Policy CodePolicy MP 2.323

Change TypeAdministrative / clarified

Effective DateFeb 1, 2025

Next Review Date

Key ActionVerify that no separate Capital Blue Cross medical policy exists for the specific genetic test; if one exists, apply that policy's criteria instead of this general policy.

SourceLink

On This Page

Panels for hereditary or genetic conditions

Intended use: Diagnostic testing of an individual's germline to benefit the individual (confirm suspected diagnosis) OR testing an asymptomatic individual to determine future risk of disease.
Panel composition: either single-condition, multiple related conditions, or clinical-syndrome panels where genetic testing identifies underlying etiologies.

Cancer panels

Intended use: testing an asymptomatic patient to determine future cancer risk (germline) OR therapeutic testing of cancer cells (somatic) to direct targeted treatment.
Panel composition: germline risk panels (e.g., BRCA) or somatic variant panels across tumor types.

Reproductive panels

Intended use: carrier testing preconception or prenatal, prenatal (in utero) testing, or preimplantation genetic testing.
Panel composition: single-disorder panels or multi-disorder screening panels for parents or fetus.

Cross-category required criteria

CLIA/licensing: Laboratory performing test is CLIA-licensed for high-complexity testing and delivers reproducible quality-filtered variant calls.
Analytic validity: Technical reliability approaches that of direct Sanger sequencing; analytic validity and methods are described and clinically valid (no clinically meaningful decrease in sensitivity/specificity).
Clinical usefulness of components: All individual components/variants in the panel have demonstrated clinical usefulness for the condition under evaluation OR the implications of variants without demonstrated utility are clear and there is no potential for incidental findings to cause harm.
Efficiency: Panel offers substantial improvement in efficiency compared with sequential single-gene testing (consider gene size, number of genes, heterogeneity).
Ancillary information impact: Impact of ancillary/investigational information is well-defined, including potential downstream testing or management changes and assessment of potential harms (false positives/negatives, incorrect risk assessment, unnecessary invasive follow-ups, reproductive decision impacts).
Decision-making defined: Decision-making based on genetic results is well-defined: results will lead to changes in diagnosis/treatment that are defined prior to testing, accord with current standard of care, and are associated with improvements in health outcomes.
Testing yield guidance: Testing yield is acceptable for target population (guidance: diagnostic hereditary disorders often >10% positive in symptomatic patients; chromosomal microarray for developmental delay recommended when yield 5-20%; cancer susceptibility testing recommended when likelihood 2-10% for BRCA/Lynch contexts).
Genetic counseling (pre- and/or post-test) by individuals with expertise in genetic medicine is recommended for at-risk patients who wish to undergo testing.

Not covered / investigational

Panels that do not meet criteria

Not covered / investigational: Genetic panels using NGS or chromosomal microarray that do not meet the criteria for a specific category or the cross-category required criteria are considered investigational due to insufficient evidence of health outcomes or benefit.

Prior Authorization

Benefit/coverage verification

Verify the member's health benefit plan language for coverage, exclusions, benefit limits, and any preauthorization requirements. Note that a medical policy does not determine benefit eligibility; benefit determinations are made from the member's plan.

Billing Rule

Use correct CPT/PLA/MAAA code

Report the appropriate CPT/PLA/MAAA code(s) based on test characteristics. Use 81410-81471 for qualifying NGS panel sequencing procedures; use specific analyte CPT codes (and 81479 once for unlisted analytes) when panel components map to analyte codes; use 815XX (or 81599 if none specific) for algorithmic multianalyte assays; and use PLA codes 0001U-0153U and 0362U as applicable.

CPT genomic sequencing panel codes: 81410-81471
Unlisted molecular pathology: 81479 (for analytes not listed)
MAAA codes: 815XX or 81599 (if algorithmic score/probability produced)
PLA codes: 0001U-0153U, 0362U

Documentation Required

Genetic counseling

Provide or document referral to genetic counseling by individuals experienced in genetic medicine for at-risk patients who undergo testing. Counseling is recommended pre- and/or post-test to help interpret results, discuss implications for the patient and family, and reduce inappropriate testing.

12/02/2022administrative update

Administrative update: PLA code 0362U added (effective 11/2023).

09/29/2023consensus review

Consensus review — no changes to policy statement; references updated.

10/24/2024consensus reviewLatest

Consensus review — no changes to policy statement; references updated.